MA51634A - Oligonucléotides antisens d'alpha-synucléine et leurs utilisations - Google Patents

Oligonucléotides antisens d'alpha-synucléine et leurs utilisations

Info

Publication number: MA51634A
Authority: MA; Morocco
Prior art keywords: synuclein; alpha; antisens; oligonucleotides; antisens oligonucleotides
Prior art date: 2018-01-12

Application number

MA051634A

Other languages

English (en)

Inventor

Jeffrey M Brown

Angela M Cacace

Martin Gill

Peter Hagedorn

Marianne Lerbech Jensen

Ivar M Macdonald

Jr Jere E Meredith

Richard E Olson

Annapurna Pendri

Original Assignee

Roche Innovation Ct Copenhagen As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-01-12

Filing date

2019-01-11

Publication date

2020-11-18

2019-01-11 Application filed by Roche Innovation Ct Copenhagen As filed Critical Roche Innovation Ct Copenhagen As

2020-11-18 Publication of MA51634A publication Critical patent/MA51634A/fr

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
102000003802 alpha-Synuclein Human genes 0.000 title 1
108090000185 alpha-Synuclein Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Neurology (AREA)
Biotechnology (AREA)
Neurosurgery (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

MA051634A 2018-01-12 2019-01-11 Oligonucléotides antisens d'alpha-synucléine et leurs utilisations MA51634A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201862616944P	2018-01-12	2018-01-12

Publications (1)

Publication Number	Publication Date
MA51634A true MA51634A (fr)	2020-11-18

Family

ID=67219416

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA051634A MA51634A (fr)	2018-01-12	2019-01-11	Oligonucléotides antisens d'alpha-synucléine et leurs utilisations

Country Status (18)

Country	Link
US (1)	US20220119811A1 (fr)
EP (1)	EP3737759A1 (fr)
JP (2)	JP2021511027A (fr)
KR (1)	KR20200109338A (fr)
CN (1)	CN112424353A (fr)
AU (2)	AU2019207859A1 (fr)
BR (1)	BR112020012921A2 (fr)
CA (1)	CA3085964A1 (fr)
CL (1)	CL2020001810A1 (fr)
CO (1)	CO2020008988A2 (fr)
CR (1)	CR20200301A (fr)
IL (1)	IL275950A (fr)
MA (1)	MA51634A (fr)
MX (1)	MX2020006973A (fr)
PE (1)	PE20210172A1 (fr)
PH (1)	PH12020500570A1 (fr)
SG (1)	SG11202006142PA (fr)
WO (1)	WO2019138057A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112019016374A2 (pt)	2017-02-17	2020-04-07	Bristol-Myers Squibb Company	anticorpos para alfa-sinucleína e usos dos mesmos
MX2020007433A (es)	2018-01-12	2020-09-14	Bristol Myers Squibb Co	Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos.
EA202091693A1 (ru)	2018-01-12	2021-04-14	Бристол-Маерс Сквибб Компани	Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения
AU2019218987B2 (en)	2018-02-12	2025-04-24	Ionis Pharmaceuticals, Inc.	Modified compounds and uses thereof
MX2020013930A (es)	2018-06-22	2021-03-09	Hoffmann La Roche	Oligonucleotidos para modular la expresion del canal de sodio dependiente de voltaje alfa subunidad 9 (scn9a).
BR112021000538A2 (pt)	2018-07-13	2021-04-06	F. Hoffmann-La Roche Ag	Oligonucleotídeos para modular a expressão de rtel1
US20210214727A1 (en) *	2019-12-20	2021-07-15	Hoffmann-La Roche Inc.	Enhanced oligonucleotides for inhibiting scn9a expression
AU2021206182A1 (en) *	2020-01-06	2022-07-28	AUM LifeTech, Inc.	Antisense oligonucleotides for treatment of neurological disorders
CA3193830A1 (fr) *	2020-10-01	2022-04-07	Mangala Meenakshi Soundarapandian	Compositions a base d'arni de snca et leurs procedes d'utilisation pour traiter ou prevenir des maladies neurodegeneratives associees a snca
PE20240696A1 (es) *	2021-03-08	2024-04-10	Servier Lab	Oligonucleotidos antisentido para inhibir la expresion de la alfa-sinucleina
CN118526514A (zh) *	2022-10-26	2024-08-23	武汉科技大学	一种促进缺血性脑卒中后血管新生的核酸药物及其应用
CN121287919B (zh) *	2025-12-03	2026-03-03	华南理工大学	α-突触核蛋白的表达调控及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ATE239484T1 (de)	1991-10-24	2003-05-15	Isis Pharmaceuticals Inc	Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
JP3756313B2 (ja)	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
DE69829760T3 (de)	1997-09-12	2016-04-14	Exiqon A/S	Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
KR100573231B1 (ko)	1999-02-12	2006-04-24	상꾜 가부시키가이샤	신규 뉴클레오시드 및 올리고뉴클레오티드 유사체
AU776362B2 (en)	1999-05-04	2004-09-09	Roche Innovation Center Copenhagen A/S	L-ribo-LNA analogues
US6617442B1 (en)	1999-09-30	2003-09-09	Isis Pharmaceuticals, Inc.	Human Rnase H1 and oligonucleotide compositions thereof
US7511131B2 (en) *	2002-11-13	2009-03-31	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
WO2006006948A2 (fr)	2002-11-14	2006-01-19	Dharmacon, Inc.	Methodes et compositions permettant de selectionner des arnsi presentant une fonctionnalite amelioree
EP2752488B1 (fr)	2002-11-18	2020-02-12	Roche Innovation Center Copenhagen A/S	Conception antisens
CA2542232A1 (fr) *	2003-06-09	2005-01-20	Alnylam Pharmaceuticals, Inc.	Methode de traitement des maladies neurodegeneratives par inhibation de l'alpha-synucleine
WO2005045034A2 (fr)	2003-10-23	2005-05-19	Sirna Therapeutics, Inc.	Traitement medie par interference arn de la maladie de parkinson au moyen d'un petit acide nucleique interferent (sina)
CA2580189C (fr)	2004-09-29	2013-05-21	Children's Memorial Hospital	Silencage genique induit par arnsi de la synucleine
US20080003570A1 (en)	2004-12-22	2008-01-03	The General Hospital Corporation	Translation enhancer elements of genes encoding human Tau protein and human alpha-synuclein protein
WO2007031091A2 (fr)	2005-09-15	2007-03-22	Santaris Pharma A/S	Composes antagonistes d'arn de modulation de l'expression de p21 ras
CA2640171C (fr)	2006-01-27	2014-10-28	Isis Pharmaceuticals, Inc.	Analogues d'acides nucleiques bicycliques modifies en position 6
CA3044969A1 (fr)	2006-05-05	2007-12-21	Ionis Pharmaceuticals, Inc.	Composes et procedes de modulation de l'expression genique
US7666854B2 (en)	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
JP5441688B2 (ja)	2006-05-11	2014-03-12	アイシスファーマシューティカルズ，インコーポレーテッド	５’修飾二環式核酸類似体
GB0610183D0 (en)	2006-05-23	2006-06-28	Isis Innovation	Treatment of neurodegenerative diseases
WO2008109509A1 (fr)	2007-03-02	2008-09-12	Mdrna, Inc.	Composés d'acide nucléique pour inhiber l'expression du gène snca et utilisations de ceux-ci
US8580756B2 (en)	2007-03-22	2013-11-12	Santaris Pharma A/S	Short oligomer antagonist compounds for the modulation of target mRNA
ES2559859T3 (es) *	2007-05-16	2016-02-16	The Brigham And Women's Hospital, Inc.	Tratamiento de sinucleinopatías
EP2170917B1 (fr)	2007-05-30	2012-06-27	Isis Pharmaceuticals, Inc.	Analogues d'acides nucléiques bicycliques pontés par aminométhylène n-substitué
ES2386492T3 (es)	2007-06-08	2012-08-21	Isis Pharmaceuticals, Inc.	Análogos de ácidos nucleicos bicíclicos carbocíclicos
CN101796062B (zh)	2007-07-05	2014-07-30	Isis制药公司	6-双取代双环核酸类似物
WO2009067647A1 (fr)	2007-11-21	2009-05-28	Isis Pharmaceuticals, Inc.	Analogues d'acide nucléique alpha-l-bicyclique carbocyclique
US20090176729A1 (en)	2007-12-14	2009-07-09	Alnylam Pharmaceuticals, Inc.	Method of treating neurodegenerative disease
WO2009124238A1 (fr)	2008-04-04	2009-10-08	Isis Pharmaceuticals, Inc.	Composés oligomères comprenant des nucléosides bicycliques terminaux liés de façon neutre
DK2356129T3 (da)	2008-09-24	2013-05-13	Isis Pharmaceuticals Inc	Substituerede alpha-L-bicykliske nukleosider
WO2011017521A2 (fr)	2009-08-06	2011-02-10	Isis Pharmaceuticals, Inc.	Analogues d'acides nucléiques cyclohexoses bicycliques
US20120277158A1 (en)	2009-10-06	2012-11-01	Angiochem Inc.	Compositions and methods for the transport of therapeutic agents
EP2490699A1 (fr)	2009-10-20	2012-08-29	Santaris Pharma A/S	Administration orale d'oligonucléotides de lna thérapeutiquement efficaces
KR20130103662A (ko)	2010-04-19	2013-09-24	엔라이프 떼라퓨틱스, 에스.엘.	올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법
EP2580228B1 (fr)	2010-06-08	2016-03-23	Ionis Pharmaceuticals, Inc.	2' amino- et 2' thio-nucléosides bicycliques substitués et composés oligomères préparés à partir de ces derniers
WO2012027713A2 (fr) *	2010-08-26	2012-03-01	Alnylam Pharmaceuticals, Inc.	Compositions et méthodes d'inhibition de la snca
WO2012068405A2 (fr) *	2010-11-17	2012-05-24	Isis Pharmaceuticals, Inc.	Modulation de l'expression de l'alpha synucléine
KR20140031217A (ko)	2011-04-20	2014-03-12	로슈 글리카트 아게	혈액-뇌 차단벽의 pH 의존적 통과를 위한 방법 및 구축물
US10023861B2 (en)	2011-08-29	2018-07-17	Ionis Pharmaceuticals, Inc.	Oligomer-conjugate complexes and their use
CA2863253A1 (fr)	2011-09-07	2013-03-14	Marina Biotech, Inc.	Synthese et utilisations de composes acides nucleiques comportant des monomeres restreints de point de vue conformationnel
EP2850092B1 (fr)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Analogues tricycliques d'acide nucléique
HK1214179A1 (zh)	2012-10-26	2016-07-22	恩莱弗医疗有限公司	通过选择性递送寡核苷酸分子至特定神经元类型治疗帕金森病的组合物和方法
JP6452614B2 (ja)	2012-11-15	2019-01-16	ロシュイノベーションセンターコペンハーゲンエーエス	オリゴヌクレオチドコンジュゲート
PE20152002A1 (es)	2013-05-01	2016-01-21	Isis Pharmaceuticals Inc	Composiciones y metodos para modular la expresion de ttr y vhb
SG10201908122XA (en)	2013-06-27	2019-10-30	Roche Innovation Ct Copenhagen As	Antisense oligomers and conjugates targeting pcsk9
WO2016061263A1 (fr) *	2014-10-14	2016-04-21	Ionis Pharmaceuticals, Inc.	Composés antisens et leurs utilisations

2019
- 2019-01-11 KR KR1020207023137A patent/KR20200109338A/ko not_active Ceased
- 2019-01-11 US US15/733,369 patent/US20220119811A1/en not_active Abandoned
- 2019-01-11 JP JP2020538687A patent/JP2021511027A/ja active Pending
- 2019-01-11 CA CA3085964A patent/CA3085964A1/fr not_active Abandoned
- 2019-01-11 MX MX2020006973A patent/MX2020006973A/es unknown
- 2019-01-11 CN CN201980018956.5A patent/CN112424353A/zh active Pending
- 2019-01-11 CR CR20200301A patent/CR20200301A/es unknown
- 2019-01-11 SG SG11202006142PA patent/SG11202006142PA/en unknown
- 2019-01-11 EP EP19700779.2A patent/EP3737759A1/fr not_active Withdrawn
- 2019-01-11 AU AU2019207859A patent/AU2019207859A1/en not_active Abandoned
- 2019-01-11 WO PCT/EP2019/050661 patent/WO2019138057A1/fr not_active Ceased
- 2019-01-11 PE PE2020000923A patent/PE20210172A1/es unknown
- 2019-01-11 BR BR112020012921-6A patent/BR112020012921A2/pt not_active IP Right Cessation
- 2019-01-11 MA MA051634A patent/MA51634A/fr unknown
2020
- 2020-06-25 PH PH12020500570A patent/PH12020500570A1/en unknown
- 2020-07-06 CL CL2020001810A patent/CL2020001810A1/es unknown
- 2020-07-09 IL IL275950A patent/IL275950A/en unknown
- 2020-07-22 CO CONC2020/0008988A patent/CO2020008988A2/es unknown
2022
- 2022-06-29 JP JP2022104277A patent/JP2022130597A/ja active Pending
- 2022-09-01 AU AU2022224819A patent/AU2022224819A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP3737759A1 (fr)	2020-11-18
CN112424353A (zh)	2021-02-26
AU2019207859A1 (en)	2020-07-02
US20220119811A1 (en)	2022-04-21
IL275950A (en)	2020-08-31
JP2021511027A (ja)	2021-05-06
SG11202006142PA (en)	2020-07-29
RU2020126575A3 (fr)	2022-02-14
MX2020006973A (es)	2020-09-09
BR112020012921A2 (pt)	2020-12-08
CL2020001810A1 (es)	2020-11-27
JP2022130597A (ja)	2022-09-06
PH12020500570A1 (en)	2021-05-10
CR20200301A (es)	2020-10-26
AU2022224819A1 (en)	2022-09-29
KR20200109338A (ko)	2020-09-22
PE20210172A1 (es)	2021-01-29
CA3085964A1 (fr)	2019-07-18
CO2020008988A2 (es)	2020-08-31
WO2019138057A1 (fr)	2019-07-18
RU2020126575A (ru)	2022-02-14

Publication	Publication Date	Title
MA51634A (fr)	2020-11-18	Oligonucléotides antisens d'alpha-synucléine et leurs utilisations
EP3914259A4 (fr)	2023-05-17	Oligonucléotides d'édition d'arn et leurs utilisations
EP3820495A4 (fr)	2022-07-20	Modificateurs d'arn épigénétiques programmables par arn et leurs utilisations
EP3914260A4 (fr)	2023-05-17	Oligonucléotides d'édition d'arn et leurs utilisations
EP3980437A4 (fr)	2023-12-06	Amidites d'una et leurs utilisations
EP3829649A4 (fr)	2022-05-04	Complexes de ciblage musculaire et leurs utilisations
EP3758729A4 (fr)	2021-11-17	Conjugués d'il-15 et leurs utilisations
EP3817769A4 (fr)	2022-03-30	Anticorps anti-cd47 humains et leurs utilisations
EP3359644A4 (fr)	2019-08-14	Nouvelles nucléases guidé par l'arn et leurs utilisations
EP3794037A4 (fr)	2022-03-02	Anticorps anti-claudine 18.2 et leurs utilisations
EP3813877A4 (fr)	2022-05-11	Compositions anti-cd24 et leurs utilisations
EP3762031A4 (fr)	2021-12-22	Anticorps anti-claudine 18.2 et leurs utilisations
EP3727371A4 (fr)	2021-10-27	Inhibiteurs d'hétéromères gpcr et leurs utilisations
EP3630199A4 (fr)	2021-11-10	Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630788A4 (fr)	2021-04-28	Compositions d'oligonucléotides et leurs procédés d'utilisation
MA50618A (fr)	2020-08-12	Polyrhérapies et leurs utilisations
EP3706801C0 (fr)	2026-01-14	Complexes de platine et leurs utilisations
EP3846807A4 (fr)	2022-05-18	Composés d'imidazoquinoléine et leurs utilisations
EP4093768A4 (fr)	2023-11-15	Constructions cal-t et leurs utilisations
EP3681912A4 (fr)	2021-06-09	Anticorps spécifiques d'axl et leurs utilisations
EP3302490A4 (fr)	2019-01-23	Inhibiteurs d'autotaxine et leurs utilisations
EP3870162A4 (fr)	2022-08-24	Inhibiteurs de ssao et leurs utilisations
EP3966321A4 (fr)	2023-09-06	Ligases de protéine spécifiques à l'asx et leurs utilisations
EP3709998A4 (fr)	2021-07-07	Nouveaux composés d'imidazopyrimidine et leurs utilisations
EP3585814A4 (fr)	2021-04-14	Agents de liaison à l'egfr et leurs utilisations